The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis

Frontiers in Oncology

Volumn 4, Issue NOV, 2014, Pages

  Ganguly, Sourik S ^a   Li, Xiaohong ^a   Miranti, Cindy K ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Bone metastasis; Cancer; EMT; Prostate; Tumor microenvironment

Indexed keywords

ALPHA2 INTEGRIN; ALPHA6 INTEGRIN; BETA1 INTEGRIN; BETA4 INTEGRIN; BONE MORPHOGENETIC PROTEIN; CD82 ANTIGEN; DOCETAXEL; ENDOTHELIN 1; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; HEPSIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; KALININ; LAMININ 10; MATRIPTASE; MATRIX METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR; PROSTATE SPECIFIC ANTIGEN; PROTEASE NEXIN I; PROTEIN BCL XL; PROTEIN TYROSINE KINASE; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 3; VERY LATE ACTIVATION ANTIGEN 6; WNT PROTEIN;

ANGIOGENESIS; BONE METASTASIS; CANCER SURVIVAL; CELL ADHESION; CELL DIFFERENTIATION; CELL HOMING; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INFLAMMATION; MITOGENESIS; NONHUMAN; OSTEOBLAST; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; WOUND HEALING;

EID: 84915751457     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00364     Document Type: Review

References (242)

1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol (2012) 61(6):1079-92. doi: 10.1016/j.eururo.2012.02.054.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin (2013) 63(1):11-30. doi: 10.3322/caac.21166.
3. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res (2006) 12(20 Pt 2):6243s-9s. doi: 10.1158/1078-0432.CCR-06-0931.
4. Hoimes CJ, Kelly WK. Redefining hormone resistance in prostate cancer. Ther Adv Med Oncol (2010) 2(2):107-23. doi: 10.1177/1758834009356433.
5. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene (2013) 32(49):5501-11. doi: 10.1038/onc.2013.206.
6. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res (2001) 61(9):3550-5.
7. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 144(4):735-46.
8. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer (1991) 48(2):189-93.
9. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgenindependent prostate cancer. Cancer Res (2006) 66(5):2815-25. doi: 10.1158/0008-5472.can-05-4000.
10. Azzouni F, Godoy A, Li Y, Mohler J. The 5 a-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol (2012) 2012:530121. doi: 10.1155/2012/530121.
11. Zobniw CM, Causebrook A, Fong MK. Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol (2014) 6:97-105. doi: 10.2147/rru.s29003.
12. Eisermann K, Wang D, Jing Y, Pascal LE, Wang Z. Androgen receptor gene mutation, rearrangement, polymorphism. Transl Androl Urol (2013) 2(3):137-47. doi: 10.3978/j.issn.2223-4683.2013.09.15.
13. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res (2013) 73(2):483-9. doi: 10.1158/0008-5472.can-12-3630.
14. Foradori CD, Weiser MJ, Handa RJ. Non-genomic actions of androgens. Front Neuroendocrinol (2008) 29(2):169-81. doi: 10.1016/j.yfrne.2007.10.005.
15. Migliaccio A, Castoria G, Auricchio F. Analysis of androgen receptor rapid actions in cellular signaling pathways: receptor/Src association. Methods Mol Biol (2011) 776:361-70. doi: 10.1007/978-1-61779-243-4_21.
16. Corn PG. The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Manag Res (2012) 4:183-93. doi: 10.2147/CMAR.S32839.
17. Alphonso A, Alahari SK. Stromal cells and Integrins: conforming to the needs of the tumor microenvironment. Neoplasia (2009) 11(12):1264-71. doi: 10.1593/neo.91302.
18. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinomaassociated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res (1999) 59(19):5002-11.
19. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature (2004) 432(7015):332-7. doi: 10.1038/nature03096.
20. Schauer IG, Sood AK, Mok S, Liu J. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia (2011) 13(5):393-405. doi: 10.1593/neo.101720.
21. Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res (2002) 62(11):3298-307.
22. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol (2001) 166(6):2472-83.
23. Horvath LG, Henshall SM, Lee CS, Kench JG, Golovsky D, Brenner PC, et al. Lower levels of nuclear b-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer (2005) 113(3):415-22. doi: 10.1002/ijc.20599.
24. Frank SB, Miranti CK. Disruption of prostate epithelial differentiation pathways and prostate cancer development. Front Oncol (2013) 3:273. doi: 10.3389/fonc.2013.00273.
25. Schmelz M, Cress AE, Scott KM, Burger F, Cui H, Sallam K, et al. Different phenotypes in human prostate cancer: α6 or a3 integrin in cell-extracellular adhesion sites. Neoplasia (2002) 4(3):243-54. doi: 10.1038/sj/neo/7900223.
26. Danen EH, van Muijen GN, van de Wiel-van Kemenade E, Jansen KF, Ruiter DJ, Figdor CG. Regulation of integrin-mediated adhesion to laminin and collagen in human melanocytes and in non-metastatic and highly metastatic human melanoma cells. Int J Cancer (1993) 54(2):315-21.
27. Friedrichs K, Ruiz P, Franke F, Gille I, Terpe HJ, Imhof BA. High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res (1995) 55(4):901-6.
28. Ports MO, Nagle RB, Pond GD, Cress AE. Extracellular engagement of α6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis. Cancer Res (2009) 69(12):5007-14. doi: 10.1158/0008-5472.CAN-09-0354.
29. Lamb LE, Zarif JC, Miranti CK. The androgen receptor induces integrin α6β1 to promote prostate tumor cell survival via NF-kB and Bcl-xL Independently of PI3K signaling. Cancer Res (2011) 71(7):2739-49. doi: 10.1158/0008-5472.can-10-2745.
30. Sroka IC, Anderson TA, McDaniel KM, Nagle RB, Gretzer MB, Cress AE. The laminin binding integrin α6β1 in prostate cancer perineural invasion. J Cell Physiol (2010) 224(2):283-8. doi: 10.1002/jcp.22149.
31. BonkhoffH, Stein U, Remberger K. Differential expression of α6 and α2 very late antigen integrins in the normal, hyperplastic, and neoplastic prostate: simultaneous demonstration of cell surface receptors and their extracellular ligands. Hum Pathol (1993) 24(3):243-8.
32. 2 chain as a stromal cell marker of the human bone marrow microenvironment. Br J Haematol (2002) 119(1):212-20.
33. Siler U, Seiffert M, Puch S, Richards A, Torok-Storb B, Muller CA, et al. Characterization and functional analysis of laminin isoforms in human bone marrow. Blood (2000) 96(13):4194-203.
34. Jin R, Yi Y, Yull FE, Blackwell TS, Clark PE, Koyama T, et al. NF-kB gene signature predicts prostate cancer progression. Cancer Res (2014) 74(10):2763-72. doi: 10.1158/0008-5472.CAN-13-2543.
35. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-kB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer (2005) 93(9):1019-23. doi: 10.1038/sj.bjc.6602796.
36. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, et al. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res (2008) 68(16):6762-9. doi: 10.1158/0008-5472.CAN-08-0107.
37. Fornaro M, Tallini G, Zheng DQ, Flanagan WM, Manzotti M, Languino LR. p27(kip1) acts as a downstream effector of and is coexpressed with the β1C integrin in prostatic adenocarcinoma. J Clin Invest (1999) 103(3):321-9. doi: 10.1172/jci4585.
38. Pontes-Junior J, Reis ST, Dall'Oglio M, Neves de Oliveira LC, Cury J, Carvalho PA, et al. Evaluation of the expression of integrins and cell adhesion molecules through tissue microarray in lymph node metastases of prostate cancer. J Carcinog (2009) 8:3.
39. Demetriou MC, Pennington ME, Nagle RB, Cress AE. Extracellular α6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer. Exp Cell Res (2004) 294(2):550-8. doi: 10.1016/j.yexcr.2003.11.023.
40. Pawar SC, Demetriou MC, Nagle RB, Bowden GT, Cress AE. Integrin α6 cleavage: a novel modification to modulate cell migration. Exp Cell Res (2007) 313(6):1080-9. doi: 10.1016/j.yexcr.2007.01.006.
41. Landowski TH, Gard J, Pond E, Pond GD, Nagle RB, Geffre CP, et al. Targeting integrin α6 stimulates curative-type bone metastasis lesions in a xenograft model. Mol Cancer Ther (2014) 13(6):1558-66. doi: 10.1158/1535-7163.MCT-13-0962.
42. Pawar SC, Dougherty S, Pennington ME, Demetriou MC, Stea BD, Dorr RT, et al. α6 integrin cleavage: sensitizing human prostate cancer to ionizing radiation. Int J Radiat Biol (2007) 83(11-12):761-7. doi: 10.1080/09553000701633135.
43. King TE, Pawar SC, Majuta L, Sroka IC, Wynn D, Demetriou MC, et al. The role of α6 integrin in prostate cancer migration and bone pain in a novel xenograft model. PLoS One (2008) 3(10):e3535. doi: 10.1371/journal.pone.0003535.
44. Miranti CK. Controlling cell surface dynamics and signaling: how CD82/KAI1 suppresses metastasis. Cell Signal (2009) 21(2):196-211. doi: 10.1016/j.cellsig.2008.08.023.
45. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science (1995) 268(5212):884-6.
46. Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res (1996) 56(19):4387-90.
47. He B, Liu L, Cook GA, Grgurevich S, Jennings LK, Zhang XA. Tetraspanin CD82 attenuates cellular morphogenesis through down-regulating integrin α6-mediated cell adhesion. J Biol Chem (2005) 280(5):3346-54. doi: 10.1074/jbc. M406680200.
48. Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrindependent crosstalk with c-Met receptor and Src kinases. Oncogene (2006) 25(16):2367-78 doi: 10.1038/sj.onc.1209269.
49. Han SY, Lee M, Hong YK, Hwang S, Choi G, Suh YS, et al. Tsp66E, the Drosophila KAI1 homologue, and Tsp74F function to regulate ovarian follicle cell and wing development by stabilizing integrin localization. FEBS Lett (2012) 586(22):4031-7. doi: 10.1016/j.febslet.2012.09.044.
50. Termini CM, Cotter ML, Marjon KD, Buranda T, Lidke KA, Gillette JM. The membrane scaffold CD82 regulates cell adhesion by altering a4 integrin stability and molecular density. Mol Biol Cell (2014) 25(10):1560-73. doi: 10.1091/mbc. E13-11-0660.
51. Abe M, Sugiura T, Takahashi M, Ishii K, Shimoda M, Shirasuna K. A novel function of CD82/KAI-1 on E-cadherin-mediated homophilic cellular adhesion of cancer cells. Cancer Lett (2008) 266(2):163-70. doi: 10.1016/j.canlet.2008.02.058.
52. Sottnik JL, Daignault-Newton S, Zhang X, Morrissey C, Hussain MH, Keller ET, et al. Integrin α2β1 (α2β1) promotes prostate cancer skeletal metastasis. Clin Exp Metastasis (2013) 30(5):569-78. doi: 10.1007/s10585-012-9561-6.
53. Ziaee S, Chung LW. Induction of integrin α2 in a highly bone metastatic human prostate cancer cell line: roles of RANKL and AR under three-dimensional suspension culture. Mol Cancer (2014) 13:208. doi: 10.1186/1476-4598-13-208.
54. Mason SD, Joyce JA. Proteolytic networks in cancer. Trends Cell Biol (2011) 21(4):228-37. doi: 10.1016/j.tcb.2010.12.002.
55. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell (2004) 6(2):185-95. doi: 10.1016/j.ccr.2004.07.008.
56. Jung H, Lee KP, Park SJ, Park JH, Jang YS, Choi SY, et al. TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition. Oncogene (2008) 27(18):2635-47. doi: 10.1038/sj.onc.1210914.
57. Tang X, Mahajan SS, Nguyen LT, Beliveau F, Leduc R, Simon JA, et al. Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis. Oncotarget (2014) 5(5):1352-62.
58. Holt SK, Kwon EM, Lin DW, Ostrander EA, Stanford JL. Association of hepsin gene variants with prostate cancer risk and prognosis. Prostate (2010) 70(9):1012-9. doi: 10.1002/pros.21135.
59. Kim HJ, Han JH, Chang IH, Kim W, Myung SC. Variants in the HEPSIN gene are associated with susceptibility to prostate cancer. Prostate Cancer Prostatic Dis (2012) 15(4):353-8. doi: 10.1038/pcan.2012.17.
60. Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates prohepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Letters (2005) 579(9):1945-50. doi: 10.1016/j.febslet.2005.01.085.
61. Tripathi M, Nandana S, Yamashita H, Ganesan R, Kirchhofer D, Quaranta V. Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression. J Biol Chem (2008) 283(45):30576-84. doi: 10.1074/jbc. M802312200.
62. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 412(6849):822-6. doi: 10.1038/35090585.
63. Wu SR, Cheng TS, Chen WC, Shyu HY, Ko CJ, Huang HP, et al. Matriptase is involved in ErbB-2-induced prostate cancer cell invasion. Am J Pathol (2010) 177(6):3145-58. doi: 10.2353/ajpath.2010.100228.
64. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci U S A (1999) 96(20):11054-61.
65. Davis TL, Cress AE, Dalkin BL, Nagle RB. Unique expression pattern of the α6β4 integrin and laminin-5 in human prostate carcinoma. Prostate (2001) 46(3):240-8.
66. Kiyomiya K, Lee MS, Tseng IC, Zuo H, Barndt RJ, Johnson MD, et al. Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells. Am J Physiol Cell Physiol (2006) 291(1):C40-9. doi: 10.1152/ajpcell.00351.2005.
67. Miller GS, List K. The matriptase-prostasin proteolytic cascade in epithelial development and pathology. Cell Tissue Res (2013) 351(2):245-53. doi: 10.1007/s00441-012-1348-1.
68. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev (2000) 14(19):2410-34.
69. Chen YW, Lee MS, Lucht A, Chou FP, Huang W, Havighurst TC, et al. TMPRSS2, a serine protease expressed in the prostate on the apical surface of luminal epithelial cells and released into semen in prostasomes, is misregulated in prostate cancer cells. Am J Pathol (2010) 176(6):2986-96. doi: 10.2353/ajpath.2010.090665.
70. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol (2003) 21(2):383-91.
71. Lucas JM, True L, Hawley S, Matsumura M, Morrissey C, Vessella R, et al. The androgenregulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. J Pathol (2008) 215(2):118-25. doi: 10.1002/path.2330.
72. Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol (2011) 3(12):1-24. doi: 10.1101/cshperspect.a005058.
73. Westermarck J, Kähäri VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J (1999) 13(8):781-92.
74. Loo WT, Cheung MN, Chow LW. Production of matrix metalloproteinases in specific subpopulations of human-patient breast cancer invading in three dimensional cultural system. Life Sci (2004) 76(7):743-52. doi: 10.1016/j.lfs.2004.06.027.
75. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol (2000) 18(5):1135-49.
76. Benaud C, Dickson RB, Thompson EW. Matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat (1998) 50(2):97-116.
77. Ganguly SS, Fiore LS, Sims JT, Friend JW, Srinivasan D, Thacker MA, et al. c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. Oncogene (2012) 31(14):1804-16. doi: 10.1038/onc.2011.361.
78. Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S, et al. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. UROL RES (2005) 33(1):44-50. doi: 10.1007/s00240-004-0440-8.
79. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, et al. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression of human prostate cancer. Clin Cancer Res (1997) 15(3):246-58.
80. Incorvaia L, Badalamenti G, Rini G, Arcara C, Fricano S, Sferrazza C, et al. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. AntiCancer Res (2007) 27(3B):1519-25.
81. Pulukuri SM, Rao JS. Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int J Oncol (2008) 32(4):757-65.
82. Xu D, McKee CM, Cao Y, Ding Y, Kessler BM, Muschel RJ. Matrix metalloproteinase-9 regulates tumor cell invasion through cleavage of protease nexin-1. Cancer Res (2010) 70(17):6988-98. doi: 10.1158/0008-5472.CAN-10-0242.
83. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, et al. RNA interferencedirected knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem (2005) 280(43):36529-40. doi: 10.1074/jbc. M503111200.
84. Jin JK, Dayyani F, Gallick GE. Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer (2011) 128(11):2545-61. doi: 10.1002/ijc.26024.
85. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 295(5564):2387-92. doi: 10.1126/science.1067100.
86. Cheng TS, Chen WC, Lin YY, Tsai CH, Liao CI, Shyu HY, et al. Curcumin-targeting pericellular serine protease matriptase role in suppression of prostate cancer cell invasion, tumor growth, and metastasis. Cancer Prev Res (Phila) (2013) 6(5):495-505. doi: 10.1158/1940-6207.CAPR-12-0293-T.
87. Ganesan R, Eigenbrot C, Kirchhofer D. Structural and mechanistic insight into how antibodies inhibit serine proteases. Biochem J (2010) 430(2):179-89. doi: 10.1042/bj20100634.
88. Ihara S, Miyoshi E, Ko JH, Murata K, Nakahara S, Honke K, et al. Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1-6 GlcNAc branching. J Biol Chem (2002) 277(19):16960-7. doi: 10.1074/jbc. M200673200.
89. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
90. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol (2014) 15(3):178-96. doi: 10.1038/nrm3758.
91. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell (2008) 133(4):704-15. doi: 10.1016/j.cell.2008.03.027.
92. Rybinski B, Franco-Barraza J, Cukierman E. The wound healing, chronic fibrosis, and cancer progression triad. Physiol Genomics (2014) 46(7):223-44. doi: 10.1152/physiolgenomics.00158.2013.
93. Adams CL, Chen YT, Smith SJ, Nelson WJ. Mechanisms of epithelial cell-cell adhesion and cell compaction revealed by high-resolution tracking of E-cadherin-green fluorescent protein. J CELL BIOL (1998) 142(4):1105-19.
94. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res (1994) 54(14):3929-33.
95. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 24(18):1967-2000. doi: 10.1101/gad.1965810.
96. Chaudhry P, Fabi F, Singh M, Parent S, Leblanc V, Asselin E. Prostate apoptosis response-4 mediates TGF-b-induced epithelial-to-mesenchymal transition. Cell Death Dis (2014) 5:e1044. doi: 10.1038/cddis.2014.7.
97. Derynck R, Akhurst RJ, Balmain A. TGF-b signaling in tumor suppression and cancer progression. Nat Genet (2001) 29(2):117-29. doi: 10.1038/ng1001-117.
98. Garg M. Epithelial-mesenchymal transition - activating transcription factors - multifunctional regulators in cancer. World J Stem Cells (2013) 5(4):188-95. doi: 10.4252/wjsc.v5.i4.188.
99. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, et al. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-b mediated epithelial-mesenchymal transition. Nat Cell Biol (2009) 11(8):943-50. doi: 10.1038/ncb1905.
100. Zavadil J, Bottinger EP. TGF-b and epithelial-to-mesenchymal transitions. Oncogene (2005) 24(37):5764-74. doi: 10.1038/sj.onc.1208927.
101. Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol (2014) 16(6):488-94. doi: 10.1038/ncb2976.
102. Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktas M, et al. Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol (2011) 179(1):400-10. doi: 10.1016/j.ajpath.2011.03.028.
103. Jacob S, Nayak S, Fernandes G, Barai RS, Menon S, Chaudhari UK, et al. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-tomesenchymal transition in prostate cancer. Endocr Relat Cancer (2014) 21(3):473-86. doi: 10.1530/erc-13-0514.
104. He H, Yang X, Davidson AJ, Wu D, Marshall FF, Chung LW, et al. Progressive epithelial to mesenchymal transitions in ARCaP E prostate cancer cells during xenograft tumor formation and metastasis. Prostate (2010) 70(5):518-28. doi: 10.1002/pros.21086.
105. Etzioni R, Cha R, Feuer EJ, Davidov O. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol (1998) 148(8):775-85.
106. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelialmesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell (2012) 22(6):725-36. doi: 10.1016/j.ccr.2012.09.022.
107. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell (2011) 20(5):576-90. doi: 10.1016/j.ccr.2011.09.009.
108. Vral A, Magri V, Montanari E, Gazzano G, Gourvas V, Marras E, et al. Topographic and quantitative relationship between prostate inflammation, proliferative inflammatory atrophy and low-grade prostate intraepithelial neoplasia: a biopsy study in chronic prostatitis patients. Int J Oncol (2012) 41(6):1950-8. doi: 10.3892/ijo.2012.1646.
109. Kwon OJ, Zhang L, Ittmann MM, Xin L. Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A (2014) 111(5):E592-600. doi: 10.1073/pnas.1318157111.
110. Valencia T, Kim JY, Abu-Baker S, Moscat-Pardos J, Ahn CS, Reina-Campos M, et al. Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell (2014) 26(1):121-35. doi: 10.1016/j.ccr.2014.05.004.
111. Brennen WN, Denmeade SR, Isaacs JT. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer (2013) 20(5):R269-90. doi: 10.1530/erc-13-0151.
112. Herroon MK, Rajagurubandara E, Hardaway AL, Powell K, Turchick A, Feldmann D, et al. Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms. Oncotarget (2013) 4(11):2108-23.
113. Nguyen DP, Li J, Yadav SS, Tewari AK. Recent insights into NF-kB signalling pathways and the link between inflammation and prostate cancer. BJU Int (2014) 114(2):168-76. doi: 10.1111/bju.12488.
114. Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, et al. The tumor-promoting actions of TNF-a involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest (2009) 119(10):3011-23. doi: 10.1172/JCI39065.
115. Sullivan DE, Ferris M, Nguyen H, Abboud E, Brody AR. TNF-a induces TGF-ß1expression in lung fibroblasts at the transcriptional levelviaAP-1 activation. Journal of Cellular and Molecular Medicine (2009) 13(8b):1866-76. doi: 10.1111/j.1582-4934.2008.00647.x.
116. Bates RC, Mercurio AM. Tumor necrosis factor-a stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell (2003) 14(5):1790-800. doi: 10.1091/mbc. E02-09-0583.
117. Kokudo T, Suzuki Y, Yoshimatsu Y, Yamazaki T, Watabe T, Miyazono K. Snail is required for TGFbeta-induced endothelial-mesenchymal transition of embryonic stem cell-derived endothelial cells. J Cell Sci (2008) 121(Pt 20):3317-24. doi: 10.1242/jcs.028282.
118. Naber HP, Drabsch Y, Snaar-Jagalska BE, ten Dijke P, van Laar T. Snail and Slug, key regulators of TGF-b-induced EMT, are sufficient for the induction of single-cell invasion. Biochem Biophys Res Commun (2013) 435(1):58-63. doi: 10.1016/j.bbrc.2013.04.037.
119. Wang H, Wang HS, Zhou BH, Li CL, Zhang F, Wang XF, et al. Epithelial-mesenchymal transition (EMT) induced by TNF-a requires AKT/GSK-3beta-mediated stabilization of snail in colorectal cancer. PLoS One (2013) 8(2):e56664. doi: 10.1371/journal.pone.0056664.
120. Li X, Xu Y, Chen Y, Chen S, Jia X, Sun T, et al. SOX2 promotes tumor metastasis by stimulating epithelial-to-mesenchymal transition via regulation of WNT/beta-catenin signal network. Cancer Lett (2013) 336(2):379-89. doi: 10.1016/j.canlet.2013.03.027.
121. Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis (2010) 13(3):228-37. doi: 10.1038/pcan.2010.23.
122. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 310(5748):644-8. doi: 10.1126/science.1117679.
123. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res (2010) 70(17):6735-45. doi: 10.1158/0008-5472.can-10-0244.
124. Michieli P. Hypoxia, angiogenesis and cancer therapy: to breathe or not to breathe? Cell Cycle (2009) 8(20):3291-6.
125. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 3(4):347-61.
126. Zhao JH, Luo Y, Jiang YG, He DL, Wu CT. Knockdown of b-Catenin through shRNA cause a reversal of EMT and metastatic phenotypes induced by HIF-1a. Cancer Invest (2011) 29(6):377-82. doi: 10.3109/07357907.2010.512595.
127. Boyce BF, Yoneda T, Guise TA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer (1999) 6(3):333-47.
128. Giunciuglio D, Cai T, Filanti C, Manduca P, Albini A. Effect of osteoblast supernatants on cancer cell migration and invasion. Cancer Lett (1995) 97(1):69-74.
129. Jacob K, Webber M, Benayahu D, Kleinman HK. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res (1999) 59:4453.
130. Festuccia C, Bologna M, Gravina GL, Guerra F, Angelucci A, Villanova I, et al. Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int J Cancer (1999) 81(3):395-403.
131. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res (2010) 16(11):2927-31. doi: 10.1158/1078-0432.CCR-09-2329.
132. Salazar N, Castellan M, Shirodkar SS, Lokeshwar BL. Chemokines and chemokine receptors as promoters of prostate cancer growth and progression. Crit Rev Eukaryot Gene Expr (2013) 23(1):77-91.
133. Das Roy L, Pathangey LB, Tinder TL, Schettini JL, Gruber HE, Mukherjee P. Breastcancer-associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Res (2009) 11(4):R56. doi: 10.1186/bcr2345.
134. Uygur B, Wu WS. SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis. Mol Cancer (2011) 10:139. doi: 10.1186/1476-4598-10-139.
135. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res (2005) 20(2):318-29. doi: 10.1359/JBMR.041109.
136. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone Cancer Res (2002) 16(6):1832-7.
137. Conley-LaComb MK, Saliganan A, Kandagatla P, Chen YQ, Cher ML, Chinni SR. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. Mol Cancer (2013) 12(1):85. doi: 10.1186/1476-4598-12-85.
138. Shiozawa Y, Pienta KJ, Taichman RS. Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin Cancer Res (2011) 17(17):5553-8. doi: 10.1158/1078-0432.CCR-10-2505.
139. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer (2009) 9(4):285-93. doi: 10.1038/nrc2621.
140. Langley RR, Fidler IJ. The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer (2011) 128(11):2527-35. doi: 10.1002/ijc.26031.
141. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 438(7069):820-7. doi: 10.1038/nature04186.
142. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol (2006) 8(12):1369-75. doi: 10.1038/ncb1507.
143. Deng J, Liu Y, Lee H, Herrmann A, Zhang W, Zhang C, et al. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell (2012) 21(5):642-654 doi: 10.1016/j.ccr.2012.03.039.
144. Zhau HE, Li CL, Chung LW. Establishment of human prostate carcinoma skeletal metastasis models. Cancer (2000) 88(12 Suppl):2995-3001.
145. Amir E, Tannock IF. Prostate cancer: Androgen deprivation therapy and bone loss. Nat Rev Urol (2009) 6(12):642-4. doi: 10.1038/nrurol.2009.218.
146. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage. Endocrinology (1997) 138(9):4013-21. doi: 10.1210/endo.138.9.5359.
147. Economos C, Morrissey C, Vessella RL. Circulating tumor cells as a marker of response: implications for determining treatment efficacy and evaluating new agents. Curr Opin Urol (2012) 22(3):190-6. doi: 10.1097/MOU.0b013e3283519b58.
148. Koop S, MacDonald IC, Luzzi K, Schmidt EE, Morris VL, Grattan M, et al. Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Res (1995) 55(12):2520-3.
149. Wikman H, Vessella R, Pantel K. Cancer micrometastasis and tumour dormancy. APMIS (2008) 116(7-8):754-70. doi: 10.1111/j.1600-0463.2008.01033.x.
150. Okazaki M, Takeshita S, Kawai S, Kikuno R, Tsujimura A, Kudo A, et al. Molecular cloning and characterization of OB-cadherin, a new member of cadherin family expressed in osteoblasts. J Biol Chem (1994) 269(16):12092-8.
151. Kawaguchi J, Kii I, Sugiyama Y, Takeshita S, Kudo A. The transition of cadherin expression in osteoblast differentiation from mesenchymal cells: consistent expression of cadherin-11 in osteoblast lineage. J Bone Miner Res (2001) 16(2):260-9. doi: 10.1359/jbmr.2001.16.2.260.
152. Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ, Chen DT, et al. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res (2008) 6(8):1259-67. doi: 10.1158/1541-7786.MCR-08-0077.
153. Huang CF, Lira C, Chu K, Bilen MA, Lee YC, Ye X, et al. Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res (2010) 70(11):4580-9. doi: 10.1158/0008-5472.CAN-09-3016.
154. Tamura D, Hiraga T, Myoui A, Yoshikawa H, Yoneda T. Cadherin-11 mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone. Int J Oncol (2008) 33(1):17-24.
155. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer (2005) 5(1):21-8. doi: 10.1038/nrc1528.
156. Mishra A, Shiozawa Y, Pienta KJ, Taichman RS. Homing of cancer cells to the bone. Cancer Microenviron (2011) 4(3):221-35. doi: 10.1007/s12307-011-0083-6.
157. Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res (2005) 15(1):57-62. doi: 10.1038/sj.cr.7290266.
158. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem (2004) 91(4):718-29. doi: 10.1002/jcb.10662.
159. Darby S, Cross SS, Brown NJ, Hamdy FC, Robson CN. BMP-6 over-expression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype. J Pathol (2008) 214(3):394-404. doi: 10.1002/path.2292.
160. Katsuno Y, Hanyu A, Kanda H, Ishikawa Y, Akiyama F, Iwase T, et al. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene (2008) 27(49):6322-33. doi: 10.1038/onc.2008.232.
161. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res (2005) 65(18):8274-85. doi: 10.1158/0008-5472.can-05-1891.
162. Bentley H, Hamdy FC, Hart KA, Seid JM, Williams JL, Johnstone D, et al. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer (1992) 66(6):1159-63.
163. Raida M, Clement JH, Ameri K, Han C, Leek RD, Harris AL. Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death. Int J Oncol (2005) 26(6):1465-70.
164. Clement JH, Raida M, Sanger J, Bicknell R, Liu J, Naumann A, et al. Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. Int J Oncol (2005) 27(2):401-7.
165. Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, et al. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res (2005) 20(12):2189-99. doi: 10.1359/JBMR.050802.
166. Abe E, Yamamoto M, Taguchi Y, Lecka-Czernik B, O'Brien CA, Economides AN, et al. Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin. J Bone Miner Res (2000) 15(4):663-73. doi: 10.1359/jbmr.2000.15.4.663.
167. Gori F, Thomas T, Hicok KC, Spelsberg TC, Riggs BL. Differentiation of human marrow stromal precursor cells: bone morphogenetic protein-2 increases OSF2/CBFA1, enhances osteoblast commitment, and inhibits late adipocyte maturation. J Bone Miner Res (1999) 14(9):1522-35. doi: 10.1359/jbmr.1999.14.9.1522.
168. Jena N, Martin-Seisdedos C, McCue P, Croce CM. BMP7 null mutation in mice: developmental defects in skeleton, kidney, and eye. Exp Cell Res (1997) 230(1):28-37.
169. Nishimura R, Hata K, Matsubara T, Wakabayashi M, Yoneda T. Regulation of bone and cartilage development by network between BMP signalling and transcription factors. J Biochem (2012) 151(3):247-54. doi: 10.1093/jb/mvs004.
170. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell (2002) 108(1):17-29.
171. Morrissey C, Brown LG, Pitts TE, Vessella RL, Corey E. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. Neoplasia (2010) 12(2):192-205.
172. Kobayashi A, Okuda H, Xing F, Pandey PR, Watabe M, Hirota S, et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med (2011) 208(13):2641-55. doi: 10.1084/jem.20110840.
173. Lee GT, Kang DI, Ha YS, Jung YS, Chung J, Min K, et al. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction. Br J Cancer (2014) 110(6):1634-44. doi: 10.1038/bjc.2014.23.
174. Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, Keller ET. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res (2008) 68(14):5785-94. doi: 10.1158/0008-5472.CAN-07-6541.
175. Godebu E, Muldong M, Strasner A, Wu C, Park S, Woo JR, et al. PCSD1, a new patientderived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. J Transl Med (2014) 12(1):275. doi: 10.1186/s12967-014-0275-1.
176. Nishimori H, Ehata S, Suzuki HI, Katsuno Y, Miyazono K. Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic proteinmediated signals. J Biol Chem (2012) 287(24):20037-46. doi: 10.1074/jbc. M112.353094.
177. Zunich SM, Douglas T, Valdovinos M, Chang T, Bushman W, Walterhouse D, et al. Paracrine sonic hedgehog signalling by prostate cancer cells induces osteoblast differentiation. Mol Cancer (2009) 8:12. doi: 10.1186/1476-4598-8-12.
178. Zunich SM, Valdovinos M, Douglas T, Walterhouse D, Iannaccone P, Lamm ML. Osteoblast-secreted collagen upregulates paracrine Sonic hedgehog signaling by prostate cancer cells and enhances osteoblast differentiation. Mol Cancer (2012) 11:30. doi: 10.1186/1476-4598-11-30.
179. Rosano L, Spinella F, Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2013) 13(9):637-51. doi: 10.1038/nrc3546.
180. Nelson JB, Udan MS, Guruli G, Pflug BR. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia (2005) 7(7):631-7.
181. Rosano L, Varmi M, Salani D, Di Castro V, Spinella F, Natali PG, et al. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res (2001) 61(22):8340-6.
182. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature (1994) 368(6473):703-10. doi: 10.1038/368703a0.
183. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med (1995) 1(9):944-9.
184. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A (2003) 100(19):10954-9. doi: 10.1073/pnas.1830978100.
185. Rahim F, Hajizamani S, Mortaz E, Ahmadzadeh A, Shahjahani M, Shahrabi S, et al. Molecular regulation of bone marrow metastasis in prostate and breast cancer. Bone Marrow Res (2014) 2014:405920. doi: 10.1155/2014/405920.
186. Chiao JW, Moonga BS, Yang YM, Kancherla R, Mittelman A, Wu-Wong JR, et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer (2000) 83(3):360-5. doi: 10.1054/bjoc.2000.1261.
187. Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol (2003) 169(3):1143-9. doi: 10.1097/01.ju.0000042162.08938.27.
188. Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. The Lancet Oncology (2013) 14(9):893-900. doi: 10.1016/s1470-2045(13)70294-8.
189. Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD, Jr., et al. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol (2007) 21(2):486-98. doi: 10.1210/me.2006-0346.
190. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 13(1):11-26. doi: 10.1038/nrc3419.
191. Kypta RM, Waxman J. Wnt/beta-catenin signalling in prostate cancer. Nat Rev Urol (2012) 9(8):418-28. doi: 10.1038/nrurol.2012.116.
192. Hall CL, Kang S, MacDougald OA, Keller ET. Role of Wnts in prostate cancer bone metastases. J Cell Biochem (2006) 97(4):661-72. doi: 10.1002/jcb.20735.
193. Yardy GW, Brewster SF. Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis (2005) 8(2):119-26. doi: 10.1038/sj.pcan.4500794.
194. Watanabe M, Kakiuchi H, Kato H, Shiraishi T, Yatani R, Sugimura T, et al. APC gene mutations in human prostate cancer. Jpn J Clin Oncol (1996) 26(2):77-81.
195. Majid S, Saini S, Dahiya R. Wnt signaling pathways in urological cancers: past decades and still growing. Mol Cancer (2012) 11:7. doi: 10.1186/1476-4598-11-7.
196. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, et al. Up-regulation of Wnt-1 and b-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer (2004) 101(6):1345-56. doi: 10.1002/cncr.20518.
197. Boissan M, De Wever O, Lizarraga F, Wendum D, Poincloux R, Chignard N, et al. Implication of metastasis suppressor NM23-H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells. Cancer Res (2010) 70(19):7710-22. doi: 10.1158/0008-5472.CAN-10-1887.
198. Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem (2005) 280(39):33132-40. doi: 10.1074/jbc. M500608200.
199. Cho YD, Yoon WJ, Kim WJ, Woo KM, Baek JH, Lee G, et al. Epigenetic modifications and canonical wingless/int-1 Class (WNT) signaling enable trans-differentiation of nonosteogenic cells into osteoblasts. J Biol Chem (2014) 289(29):20120-8. doi: 10.1074/jbc. M114.558064.
200. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res (2005) 65(17):7554-60. doi: 10.1158/0008-5472.CAN-05-1317.
201. Heldin CH. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal (2013) 11:97. doi: 10.1186/1478-811x-11-97.
202. Ustach CV, Huang W, Conley-LaComb MK, Lin CY, Che M, Abrams J, et al. A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate cancer. Cancer Res (2010) 70(23):9631-40. doi: 10.1158/0008-5472.can-10-0511.
203. Ustach CV, Taube ME, Hurst NJ, Jr., Bhagat S, Bonfil RD, Cher ML, et al. A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res (2004) 64(5):1722-9.
204. Caplan AI, Correa D. PDGF in bone formation and regeneration: new insights into a novel mechanism involving MSCs. J Orthop Res (2011) 29(12):1795-803. doi: 10.1002/jor.21462.
205. Lev DC, Kim SJ, Onn A, Stone V, Nam DH, Yazici S, et al. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res (2005) 11(1):306-14.
206. Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, et al. Inhibition of plateletderived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res (2003) 9(17):6534-44.
207. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 13(19):5816-24. doi: 10.1158/1078-0432.CCR-07-1269.
208. Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract (2014) 2014:357027. doi: 10.1155/2014/357027.
209. Erlebacher A, Derynck R. Increased expression of TGF-β2 in osteoblasts results in an osteoporosis-like phenotype. J CELL BIOL (1996) 132(1-2):195-210.
210. FilvaroffE, Erlebacher A, Ye J, Gitelman SE, Lotz J, Heillman M, et al. Inhibition of TGFbeta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development (1999) 126(19):4267-79.
211. Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, Oyajobi BO, et al. TGFbeta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res (2011) 71(3):822-31. doi: 10.1158/0008-5472.CAN-10-2993.
212. Buijs JT, Stayrook KR, Guise TA. TGF-beta in the Bone Microenvironment: Role in Breast Cancer Metastases. Cancer Microenviron (2011) 4(3):261-81. doi: 10.1007/s12307-011-0075-6.
213. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther (2007) 6(10):2609-17. doi: 10.1158/1535-7163.mct-07-0234.
214. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, et al. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci (2007) 98(1):127-33 doi: 10.1111/j.1349-7006.2006.00357.x.
215. Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, et al. TGF-b-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res (2011) 71(1):175-84. doi: 10.1158/0008-5472.CAN-10-2651.
216. Yin JJS, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser RM, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest (1999) 103(2):197-206.
217. Li X, Sterling JA, Fan KH, Vessella RL, Shyr Y, Hayward SW, et al. Loss of TGF-b responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions. Mol Cancer Res (2012) 10(4):494-503. doi: 10.1158/1541-7786.MCR-11-0506.
218. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol (2002) 3(5):298-302.
219. Grzmil M, Hemmerlein B, Thelen P, Schweyer S, Burfeind P. Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, upregulates IGF binding protein-3, and suppresses MMP-2 expression. J Pathol (2004) 202(1):50-9. doi: 10.1002/path.1492.
220. Zhao H, Dupont J, Yakar S, Karas M, LeRoith D. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene (2004) 23(3):786-94. doi: 10.1038/sj.onc.1207162.
221. Hiraga T, Myoui A, Hashimoto N, Sasaki A, Hata K, Morita Y, et al. Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res (2012) 72(16):4238-49. doi: 10.1158/0008-5472.CAN-11-3061.
222. Ryan CJ, Haqq CM, Simko J, Nonaka DF, Chan JM, Weinberg V, et al. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. urol oncol (2007) 25(2):134-40. doi: 10.1016/j.urolonc.2006.07.019.
223. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer (2004) 11(4):709-24. doi: 10.1677/erc.1.00535.
224. Abate-Shen C, Shen MM. FGF signaling in prostate tumorigenesis--new insights into epithelial-stromal interactions. Cancer Cell (2007) 12(6):495-7. doi: 10.1016/j.ccr.2007.11.021.
225. Corn PG, Wang F, McKeehan WL, Navone N. Targeting fibroblast growth factor pathways in prostate cancer. Clin Cancer Res (2013) 19(21):5856-66. doi: 10.1158/1078-0432.CCR-13-1550.
226. Dorkin TJ, Robinson MC, Marsh C, Neal DE, Leung HY. aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. J Pathol (1999) 189(4):564-9. doi: 10.1002/(SICI)1096-9896(199912)189:4<564::AID-PATH480>3.0.CO;2-1.
227. Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res (1999) 5(5):1063-71.
228. Ropiquet F, Giri D, Kwabi-Addo B, Mansukhani A, Ittmann M. Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. Cancer Res (2000) 60(15):4245-50.
229. Freeman KW, Welm BE, Gangula RD, Rosen JM, Ittmann M, Greenberg NM, et al. Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res (2003) 63(23):8256-63.
230. Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell (2007) 12(6):559-71. doi: 10.1016/j.ccr.2007.11.004.
231. Ozen M, Giri D, Ropiquet F, Mansukhani A, Ittmann M. Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst (2001) 93(23):1783-90.
232. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 118(8):2697-710. doi: 10.1172/JCI33093.
233. Valta MP, Hentunen T, Qu Q, Valve EM, Harjula A, Seppanen JA, et al. Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. Endocrinology (2006) 147(5):2171-82. doi: 10.1210/en.2005-1502.
234. Valta MP, Tuomela J, Bjartell A, Valve E, Vaananen HK, Harkonen P. FGF-8 is involved in bone metastasis of prostate cancer. Int J Cancer (2008) 123(1):22-31. doi: 10.1002/ijc.23422.
235. Teishima J, Shoji K, Hayashi T, Miyamoto K, Ohara S, Matsubara A. Relationship between the localization of fibroblast growth factor 9 in prostate cancer cells and postoperative recurrence. Prostate Cancer Prostatic Dis (2012) 15(1):8-14. doi: 10.1038/pcan.2011.48.
236. Lamb LE, Knudsen BS, Miranti CK. E-cadherin-mediated survival of androgen-receptorexpressing secretory prostate epithelial cells derived from a stratified in vitro differentiation model. J Cell Sci (2010) 123(Pt 2):266-76. doi: 10.1242/jcs.054502.
237. Foster BA, Evangelou A, Gingrich JR, Kaplan PJ, DeMayo F, Greenberg NM. Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation (2002) 70(9-10):624-32. doi: 10.1046/j.1432-0436.2002.700915.x.
238. Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA, et al. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell (2007) 12(6):572-85. doi: 10.1016/j.ccr.2007.11.002.
239. Liu W, Zhou Y, Reske SN, Shen C. PTEN mutation: many birds with one stone in tumorigenesis. AntiCancer Res (2008) 28(6A):3613-9.
240. Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, Multani A, et al. Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate (2006) 66(15):1664-73 doi: 10.1002/pros.20488.
241. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, et al. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate (2003) 55(4):239-46. doi: 10.1002/pros.10198.
242. Corey E, Quinn JE, Vessella RL. A novel method of generating prostate cancer metastases from orthotopic implants. Prostate (2003) 56(2):110-4. doi: 10.1002/pros.10235.